Pangaea Oncology SA
MAD:PANG
Pangaea Oncology SA
Pangaea Oncology SA provides molecular diagnostics and research development services in the field of personalized cancer treatment. The company is headquartered in Barcelona, Barcelona and currently employs 50 full-time employees. The company went IPO on 2016-12-29. The firm focuses on the development of oncology treatments. The Company’s activities are divided into two business lines: Clinical care in the Dr. Rosell Oncology Institute (IOR) and Molecular diagnosis (Dx). The IOR division offers personalized medical services related to oncology area, such as diagnosis, laboratory testing and treatment, in a chain of hospitals in Catalonia, Spain. The Dx division is responsible for the development of diagnostic and in-vitro services, biomarkers, as well as targeted drugs for patients and pharmaceutical companies. Its diagnostic models include Liquid Biopsy and Multiplexing.
Pangaea Oncology SA provides molecular diagnostics and research development services in the field of personalized cancer treatment. The company is headquartered in Barcelona, Barcelona and currently employs 50 full-time employees. The company went IPO on 2016-12-29. The firm focuses on the development of oncology treatments. The Company’s activities are divided into two business lines: Clinical care in the Dr. Rosell Oncology Institute (IOR) and Molecular diagnosis (Dx). The IOR division offers personalized medical services related to oncology area, such as diagnosis, laboratory testing and treatment, in a chain of hospitals in Catalonia, Spain. The Dx division is responsible for the development of diagnostic and in-vitro services, biomarkers, as well as targeted drugs for patients and pharmaceutical companies. Its diagnostic models include Liquid Biopsy and Multiplexing.
